Insulife has received positive signals from the FDA
Insulife, which is developing an insulin spray, is in talks with the US Food and Drug Administration (FDA) about a study in the US.
The Norwegian company Insulife is in the first part of the regulatory process in the US, where an overall clinical development plan is being discussed with the US Food and Drug Administration (FDA), CEO Åge Nærdal tells MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
